Gilead Sciences Stock Analysis (Episode010)
Episode 10 of the The DIY Investing Podcast podcast, hosted by Trey Henninger: Private Investor, Portfolio Manager, Business Strategist, and Value Investing Expert, titled "Gilead Sciences Stock Analysis (Episode010)" was published on January 20, 2019 and runs 43 minutes.
January 20, 2019 ·43m · The DIY Investing Podcast
Episode Description
Gilead Sciences is a biopharmaceutical company with a focus on treating and curing diseases. Their areas of focus include HIV, Hepatitis C, Oncology, Inflammation, and NASH.
Gilead Sciences (GILD)
- Business Model Overview
- HIV
- Hepatitis C
- Oncology/Cancer Treatment (KITE) – Yescarta
- Inflammation - Filgotinib
- NASH (Liver disease) – Selonsertib
- Leading cause of liver transplants. Generally related to Obesity
- Durability
- Competition
- Quality and Growth
- Capital Allocation
- Value
- Potential Errors
- Conclusion
Show Notes available at DIYInvesting.org
The full show notes for this episode, including my outline for today's podcast, are available at https://www.diyinvesting.org/Episode6
Please review and rate the podcast
If you enjoyed this podcast and found it helpful, please consider leaving me a review. On an iOS platform such as an iPhone or iPad, you can do so by following these steps:
- In your podcast app, click the search icon that looks like a magnifying glass in the bottom right-hand corner.
- Type "The DIY Investing" into the search bar. This podcast should be one of the first shows that display.
- Select the podcast show icon.
- Scroll down to the "Ratings & Reviews Section" and click on the button that says "Write a Review".
- Write a short one or two sentence review and give me a rating that matches how you feel about the podcast.
Similar Episodes
Apr 6, 2026 ·55m
Apr 1, 2026 ·26m
Mar 29, 2026 ·50m
Mar 25, 2026 ·35m
Mar 22, 2026 ·28m
Mar 18, 2026 ·25m